Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16a-18F-Fluoro-17ß-Fluoroestradiol

To guide referring and imaging physicians to use Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), American College of Nuclear Medicine (ACNM), and Lobular Breast Cancer Alliance (LBCA) worked collaboratively to develop criteria for the appropriate use of this new imaging technology.

SNMMI assembled an autonomous Workgroup to represent a multidisciplinary panel of health care providers with substantive knowledge in the use of nuclear medicine procedures in Estrogen Receptor-Targeted PET Imaging to review the scientific literature and develop consensus recommendations for the clinical use of this technology. Gary Ulaner, MD conducted a systematic review of existing evidence based on the scope and parameters the Imaging Workgroup put together, The systematic review was used to make their recommendations for clinical use.

Click here to view AUC for Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol

To view the development process, please click the following link: SNMMI AUC Development Process.